Randomized trial · people

SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a large placebo-controlled trial, elamipretide was tolerated well but did not improve walking distance or fatigue over 24 weeks in primary mitochondrial myopathy.

Kind
Randomized trial
Studied in
People
Number studied
218
Published
2023
Journal
Neurology

What they tested

The team tested whether elamipretide improves walking ability and fatigue in people with primary mitochondrial myopathy, a group of inherited conditions that harm how mitochondria make energy.

How the study was done

A phase 3, randomized, double-blind, placebo-controlled trial in 218 people with genetically confirmed primary mitochondrial myopathy. Half got 40 mg/d of elamipretide and half got placebo (a dummy shot), both under the skin, for 24 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Elamipretide missed both of the trial's main goals. On the 6-minute walk test, the gap in distance change between the elamipretide and placebo groups was -3.2 meters (95% CI -18.7 to 12.3; p = 0.69), so the groups did not differ in a meaningful way. On a fatigue questionnaire built for this condition, the gap between groups in the change in total score was -0.07 (p = 0.37), again not a meaningful difference. The drug was tolerated well, and most side effects were mild or moderate.

What it doesn’t show

The trial lasted 24 weeks and tested a single dose in people with this specific genetic muscle condition, and 94% of them were White. It does not show how elamipretide does in other conditions or over longer periods.

The paper

Karaa et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023.

The compound

More studies on SS-31

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo